Skip to main content
. Author manuscript; available in PMC: 2017 Apr 15.
Published in final edited form as: Biol Psychiatry. 2015 Mar 17;79(8):642–649. doi: 10.1016/j.biopsych.2015.03.012

Figure 2.

Figure 2

Incorporation of iPSCs can accelerate drug discovery for ASDs. Adding iPSC-derived neurons can potentially impact the time frame for screening and marketing new drugs for ASDs. As the models become more sophisticated and the cost of iPSCs becomes reduced, this type of approach may also be used to categorize the ASD-responsive populations for more efficient treatment.